Replimune Group (NASDAQ:REPL) Stock Price Down 8% – Here’s What Happened

Replimune Group, Inc. (NASDAQ:REPL)’s share price dropped 8% on Friday . The company traded as low as $6.96 and last traded at $6.9730. Approximately 1,024,169 shares were traded during trading, a decline of 25% from the average daily volume of 1,369,877 shares. The stock had previously closed at $7.58.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Replimune Group in a report on Monday, December 29th. Piper Sandler raised their target price on shares of Replimune Group from $13.00 to $14.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Finally, Wedbush boosted their price target on shares of Replimune Group from $18.00 to $19.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 4th. Six analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $10.00.

Replimune Group Price Performance

The company has a 50-day simple moving average of $7.76 and a 200-day simple moving average of $7.64. The stock has a market cap of $586.25 million, a PE ratio of -2.06 and a beta of 0.72. The company has a debt-to-equity ratio of 0.33, a current ratio of 5.60 and a quick ratio of 5.60.

Replimune Group (NASDAQ:REPL) last issued its earnings results on Tuesday, February 3rd. The company reported ($0.77) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.08. Sell-side analysts anticipate that Replimune Group, Inc. will post -2.97 EPS for the current fiscal year.

Institutional Investors Weigh In On Replimune Group

Several institutional investors have recently modified their holdings of the company. International Assets Investment Management LLC purchased a new position in Replimune Group in the 4th quarter valued at approximately $29,000. Russell Investments Group Ltd. boosted its position in shares of Replimune Group by 3,638.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock worth $33,000 after buying an additional 7,569 shares in the last quarter. CWM LLC grew its stake in Replimune Group by 248.6% in the 4th quarter. CWM LLC now owns 4,047 shares of the company’s stock valued at $39,000 after acquiring an additional 2,886 shares during the last quarter. BNP Paribas Financial Markets grew its stake in Replimune Group by 99.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 13,762 shares of the company’s stock valued at $58,000 after acquiring an additional 6,873 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new position in Replimune Group during the 2nd quarter valued at about $69,000. Hedge funds and other institutional investors own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.